Dow Up0.05% Nasdaq Down0.18%

More On WL6.DE



News & Info


Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates


  • Major Holders
  • Insider Transactions
  • Insider Roster


Wilex AG (WL6.DE)

1.86 Down 0.08(4.07%) May 5
ProfileGet Profile for:
Wilex AG
Grillparzerstrasse 18
Munich, 81675
Germany - Map
Phone: 49 89 41 31 38 0
Fax: 49 89 41 31 38 99

Index Membership:N/A
Full Time Employees:46

Business Summary 

WILEX AG operates as a biopharmaceutical company that focuses on oncology and antibodies. The company’s portfolio includes diagnostic and therapeutic product candidates for the detection and treatment of various types of cancer based on antibodies and small molecules. It develops RENCAREX, a Phase III product candidate for the treatment of clear cell renal cell carcinoma; REDECTANE, which has completed a Phase III trial for the treatment of kidney cancer; and MESUPRON that has completed Phase IIa clinical trials for the treatment of pancreatic and breast cancers. WILEX AG also provides preclinical contract services and an antibody drug conjugate technology platform. The company was formerly known as WILEX Biotechnology GmbH and changed its name to WILEX AG in February 2001. WILEX AG was founded in 1997 and is headquartered in Munich, Germany.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Wilex AG

Key Executives 
Dr. Jan Schmidt-Brand , 58
Chief Financial Officer and Member of the Exec. Management Board
Dr. Paul Bevan Ph.D., 68
Head of R&D and Member of the Exec. Board
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in EUR.